J

Joinn Laboratories China Co Ltd
SSE:603127

Watchlist Manager
Joinn Laboratories China Co Ltd
SSE:603127
Watchlist
Price: 17.01 CNY -1.79% Market Closed
Market Cap: 12.7B CNY
Have any thoughts about
Joinn Laboratories China Co Ltd?
Write Note

Joinn Laboratories China Co Ltd
Treasury Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Joinn Laboratories China Co Ltd
Treasury Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Treasury Stock CAGR 3Y CAGR 5Y CAGR 10Y
J
Joinn Laboratories China Co Ltd
SSE:603127
Treasury Stock
-ÂĄ223.1m
CAGR 3-Years
-200%
CAGR 5-Years
-115%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Treasury Stock
-ÂĄ2B
CAGR 3-Years
-4%
CAGR 5-Years
-49%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Treasury Stock
-ÂĄ479m
CAGR 3-Years
-49%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Treasury Stock
-ÂĄ18.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Treasury Stock
-ÂĄ180.8m
CAGR 3-Years
25%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Treasury Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Joinn Laboratories China Co Ltd
Glance View

Market Cap
12.8B CNY
Industry
Life Sciences Tools & Services

Nestled in the bustling heart of China's vibrant biomedical sector, Joinn Laboratories China Co Ltd has emerged as a pivotal player in advancing the field of pharmaceutical research and development. Founded with a vision to revolutionize the landscape of drug testing and safety evaluation, Joinn Laboratories operates as a comprehensive preclinical contract research organization (CRO). The company specializes in providing a wide array of services including toxicology, pharmacology, and bioanalytical testing that are crucial in the early stages of drug development. With an expansive network of state-of-the-art laboratories and a team of highly skilled scientists, Joinn facilitates the essential task of ensuring that pharmaceutical products meet rigorous safety and efficacy standards before advancing to clinical trials. Joinn Laboratories generates revenue primarily by offering these indispensable services to pharmaceutical companies and biotech firms worldwide. By acting as an external testing partner, Joinn allows its clients to significantly streamline their drug development processes, reducing both time and cost associated with bringing a new drug to market. Their business model thrives on the growing demand for outsourced R&D capabilities, a trend fueled by the increasing complexity and regulatory requirements in drug approval processes. The company leverages its expertise and cutting-edge technology to deliver precise and reliable data, thus providing a seamless bridge between scientific discovery and market-ready pharmaceutical solutions.

Intrinsic Value
16.68 CNY
Overvaluation 2%
Intrinsic Value
Price
J

See Also

What is Joinn Laboratories China Co Ltd's Treasury Stock?
Treasury Stock
-223.1m CNY

Based on the financial report for Jun 30, 2024, Joinn Laboratories China Co Ltd's Treasury Stock amounts to -223.1m CNY.

What is Joinn Laboratories China Co Ltd's Treasury Stock growth rate?
Treasury Stock CAGR 5Y
-115%

Over the last year, the Treasury Stock growth was -105%. The average annual Treasury Stock growth rates for Joinn Laboratories China Co Ltd have been -200% over the past three years , -115% over the past five years .

Back to Top